U.S. markets closed
  • S&P Futures

    3,887.00
    -11.75 (-0.30%)
     
  • Dow Futures

    31,430.00
    -79.00 (-0.25%)
     
  • Nasdaq Futures

    13,248.00
    -31.75 (-0.24%)
     
  • Russell 2000 Futures

    2,263.50
    -11.30 (-0.50%)
     
  • Crude Oil

    59.93
    -0.71 (-1.17%)
     
  • Gold

    1,712.70
    -10.30 (-0.60%)
     
  • Silver

    26.17
    -0.50 (-1.89%)
     
  • EUR/USD

    1.2026
    -0.0033 (-0.28%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3886
    -0.0035 (-0.25%)
     
  • USD/JPY

    106.8200
    +0.0900 (+0.08%)
     
  • BTC-USD

    48,889.24
    +2,344.33 (+5.04%)
     
  • CMC Crypto 200

    979.98
    +51.75 (+5.57%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,496.52
    -166.98 (-0.56%)
     

Cellectis (CLLS) Jumps: Stock Rises 9%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Cellectis S.A. CLLS was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 40.5% in the past one-month time frame.

The move came after the company withdrew its proposed underwritten offering of American Depositary Shares owing to challenging market conditions.

The company has seen one negative estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Cellectis S.A. Price

Cellectis S.A. Price
Cellectis S.A. Price

Cellectis S.A. price | Cellectis S.A. Quote

Cellectis currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

A better-ranked stock in the Medical - Biomedical and Genetics industry is Repligen Corporation RGEN, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Repligen Corporation (RGEN) : Free Stock Analysis Report
 
Cellectis S.A. (CLLS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research